Filoviruses, Ebola viruses (EBOV) and Marburg viruses (MBGV) (NIAID category A), are extremely virulent causes of viral hemorrhagic fever. Effective small molecule anti-filovirus therapies are still lacking for these important biodefense pathogens. It has been previously demonstrated that EBOV or MBGV infection impairs the capacity of cells to produce interferon (IFN)-alpha/beta and impairs cellular responses to interferon (IFN)- alpha/beta and to IFN-gamma. These capacities likely contribute to the rapid in vivo dissemination of filoviruses and promote systemic filovirus infection and facilitate the replication of filoviruses in vivo. Defining the viral factors that block cellular responses to IFN should shed light on filoviral pathogenesis. The identification of compounds that block the function of filovirus-encoded IFN-antagonists could augment the efficacy of IFN produced during the course of viral infection or the efficacy of IFN administered as an antiviral treatment. We have identified the VP24 protein of EBOV and the VP40 protein of MBGV as inhibitors of IFN signaling. This proposal will capitalize upon the identification of the EBOV VP24 and MBGV VP40 as inhibitors of IFN signaling. We have already demonstrated that the EBOV VP24 inhibits the nuclear accumulation of activated STAT1, and preliminary data demonstrates that MBGV VP40 inhibits STAT1 and STAT2 tyrosine phosphorylation. Based upon these observations, the specific aims of this proposal are to (1) Define the mechanism by which the MBGV VP40 protein inhibits host cell IFN signaling;(2) Assess the importance of VP24 and VP40 for inhibition of IFN signaling in EBOV- or MBGV-infected cells;(3) Develop screens to identify inhibitors of EBOV VP24 and MBGV VP40 IFN-antagonist function;and (4) Identify small molecules that inhibit EBOV VP24 and MBGV VP40 function.
Ebola virus and Marburg virus are important, highly lethal biodefense pathogens, and insights into their pathogenesis are badly needed. Also needed are effective therapeutics targeting these viruses. This proposal seed to define critical aspects of virus pathogenesis, how these viruses evade innate immunity, and to develop drugs that inhibit these viral functions.
|Li, Xiao-Ping; Kahn, Jennifer N; Tumer, Nilgun E (2018) Peptide Mimics of the Ribosomal P Stalk Inhibit the Activity of Ricin A Chain by Preventing Ribosome Binding. Toxins (Basel) 10:|
|Goldman, David L; Nieves, Edward; Nakouzi, Antonio et al. (2018) Serum-Mediated Cleavage of Bacillus anthracis Protective Antigen Is a Two-Step Process That Involves a Serum Carboxypeptidase. mSphere 3:|
|Marié, Isabelle J; Chang, Hao-Ming; Levy, David E (2018) HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies. J Exp Med 215:3194-3212|
|Uhde, Melanie; Ajamian, Mary; Wormser, Gary P et al. (2017) Reply to Naktin. Clin Infect Dis 64:1145-1146|
|Chen, Han; Coseno, Molly; Ficarro, Scott B et al. (2017) A Small Covalent Allosteric Inhibitor of Human Cytomegalovirus DNA Polymerase Subunit Interactions. ACS Infect Dis 3:112-118|
|Aguilar, Jorge L; Varshney, Avanish K; Pechuan, Ximo et al. (2017) Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence 8:741-750|
|Zhou, Yijun; Li, Xiao-Ping; Chen, Brian Y et al. (2017) Ricin uses arginine 235 as an anchor residue to bind to P-proteins of the ribosomal stalk. Sci Rep 7:42912|
|Lauretti, Flavio; Chattopadhyay, Anasuya; de Oliveira França, Rafael Freitas et al. (2016) Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection. Hum Vaccin Immunother 12:2327-33|
|Tadin, Ante; Tokarz, Rafal; Markoti?, Alemka et al. (2016) Molecular Survey of Zoonotic Agents in Rodents and Other Small Mammals in Croatia. Am J Trop Med Hyg 94:466-73|
|Basu, Debaleena; Li, Xiao-Ping; Kahn, Jennifer N et al. (2016) The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1. Infect Immun 84:149-61|
Showing the most recent 10 out of 655 publications